CSIR-IGIB partners with Sanofi Genzyme in the area of Rare Genetic Diseases

posted Dec 26, 2018, 1:54 AM by Vinod Scaria   [ updated Dec 26, 2018, 1:55 AM ]
Though rare genetic diseases are individually rare and encompass a spectrum of over 7000 diseases, together they amount to a significant number in the population. It is estimated that over 300 million people suffer from one or other rare genetic disease in the world. India shares a significant proportion of this, with estimates that it is home to over 30 million people with rare genetic diseases. Without a national programme for genetic diseases, and neonatal screening, many of the diseases remain undiagnosed. The diversity in social, cultural and marriage practices would also mean that many diseases run in families/communities, in some times significantly impairing the social function of the families, apart from the large economic and emotional burden these families/communities go through.

In furtherence of SANOFI GENZME’s commitment to patients of rare diseases and the CSIR–INSTITUTE OF GENOMICS & INTEGRATIVE BIOLOGY‘s aim to initiate a unique research program on Genomics for understanding rare diseases, Sanofi Genzyme, a division of Sanofi-Synthelabo (India) Pvt. Limited hereby agrees to collaborate with the CSIR–INSTITUTE OF GENOMICS & INTEGRATIVE BIOLOGY for a partnership in the area of clinical genomics & rare genetic diseases.